- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA (2018), EMA (2019))|
|International Nonproprietary Names|
|ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®|
|Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab, but was designed to have an inhherently longer circulating half-life so as to extend dosing intervals to once/month .
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
|GtoPdb PubChem SID||381118878|
|Search PubMed clinical trials||ravulizumab|
|Search PubMed titles||ravulizumab|
|Search PubMed titles/abstracts||ravulizumab|